Acute Myeloid Leukemia
Co-Pay Relief Program Fund Notices
Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!
This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.Fund Type
Co-pay, Co-Insurance & DeductibleMaximum Award Level
$3,500 Per Year
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements Medicare, Medicaid, or Military Benefits
- Must reside and receive treatment in the United States.
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a malignant disease of the bone marrow in which the DNA of a developing stem cell in the bone marrow is damaged. The damaged cell becomes a leukemic cell and multiplies into leukemic blasts, which block the production of normal cells. AML is defined by myeloblasts making up greater than 20% of the leukocytes in the peripheral blood.
AML is the most common acute leukemia in adults, accounting for approximately 80% of new acute cases, and is most common in adults older than 65. AML is the second most common form of leukemia in children during the first two years of life and during the teenage years. Major risk factors include age, having a previous diagnosis of myelodysplastic syndrome or myeloproliferative disorders, which have a risk of conversion to AML. Acute myelogenous leukemia is also known as acute myeloid leukemia, acute myeloblastic leukemia, acute granulocytic leukemia and acute nonlymphocytic leukemia.”
- Good Days877-968-7233
- Healthwell Foundation800-675-8416
- Leukemia & Lymphoma Society800-955-4572
- National Organization for Rare Disorders800-999-6673
- Needy Meds800-503-6897
- Patient Access Network Foundation866-316-7263
- Patient Services Inc.800-366-7741
- The Assistance Fund855-845-3663